title: IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
abstract: BACKGROUND
  Psoriasis is characterized by multiple genetic variations. Some of these variations, such as the presence of HLA-Cw6 or TNFAIP3 single-nucleotide polymorphisms (SNPs), have been correlated to the response to biologic treatments.
  
  
  OBJECTIVE
  The aim of our study was to evaluate the effects of IL12B and IL6 SNPs on the response to ustekinumab.
  
  
  METHODS
  We retrospectively analyzed the genotypes of 64 patients who had been treated with ustekinumab for up to 1 year. Efficacy data were evaluated using 'intention to treat-last observation carried forward' analysis.
  
  
  RESULTS
  We confirmed the positive role of HLA-Cw6 as a predictor of the response to ustekinumab and discovered that presence of the GG genotype on the IL12B rs6887695 SNP and absence of the AA genotype on the IL12B rs3212227 SNP significantly increase the probability of therapeutic success in HLA-Cw6 positive patients.
  
  
  CONCLUSIONS
  The availability of pharmacogenetic data will influence therapeutic decisions in the clinical management of psoriatic patients.
authors.affiliation: Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Galluzzo
authors.forename: Andreea Nicoleta
authors.initials: AN
authors.lastname: Boca
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Botti
authors.forename: Concetta
authors.initials: C
authors.lastname: Potenza
authors.forename: Giovanna
authors.initials: G
authors.lastname: Malara
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Malagoli
authors.forename: Stefan
authors.initials: S
authors.lastname: Vesa
authors.forename: Sergio
authors.initials: S
authors.lastname: Chimenti
authors.forename: Anca Dana
authors.initials: AD
authors.lastname: Buzoianu
authors.forename: Marina
authors.initials: M
authors.lastname: Talamonti
authors.forename: Antonio
authors.initials: A
authors.lastname: Costanzo
mesh_terms: D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D015236:HLA-C Antigens / Q000235:genetics*; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000235:genetics*; D015850:Interleukin-6 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics*; D018123:Receptors, Interleukin / Q000235:genetics; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D015236:HLA-C Antigens; C528994:HLA-C*06 antigen; C500879:IL12B protein, human; C515500:IL23R protein, human; D053762:Interleukin-12 Subunit p40; D015850:Interleukin-6; D018123:Receptors, Interleukin; D000069549:Ustekinumab